Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)

• Status: Unknown status
• Trial end date: 2021-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Prospective randomized open multicenter trial with blinded adjudication of endpoints to assess the efficacy of six-month low-dose LMWH (Low Molecular Weight Heparin) for the prevention of symptomatic or incidental VTE in patients with stage IV lung cancer and elevated D-dimer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assistance Publique - Hôpitaux de Paris
• Collaborators: Ministry of Health, France; National Cancer Institute, France
• Treatments: Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Tinzaparin

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• Social security affiliation

• Written informed consent

• Histologically confirmed stage IV (M1a or M1b) non-small-cell lung cancer, including recurrent non-small-cell lung cancer after a period of complete remission

• D-dimer > 1,500 µg/L

• First line of systemic cancer treatment (chemotherapy, immunotherapy or targeted therapy), or new line of systemic cancer treatment for cancer progression (chemotherapy, immunotherapy or targeted therapy), introduced during the month preceding inclusion or planned within one month after inclusion

• ECOG (Eastern Cooperative Oncology Group) score 0-2

• Life expectancy >3 months

Exclusion Criteria:

• Hypersensitivity to heparin or to any excipients

• Septic endocarditis

• History of heparin-induced thrombocytopenia

• Ongoing anticoagulant treatment at therapeutic dosage

• VTE at inclusion

• Creatinin clearance <30 mL/min

• Active bleeding

• Platelet count < 100 G/L at inclusion

• Severe hepatic insufficiency

• Cancer treated exclusively with supportive care

• Aspirin at daily dosage > 160 mg

• Pregnancy

• Patient under tutorship or curatorship